ResearchMoz

Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail

GBI Research
Published Date » 2012-12-31
No. Of Pages » 72
     
  Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail  
     
  Summary  
   
 Leading business intelligence provider, GBI Research, has released its latest research report, entitled: “Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail”. The report provides insights into the liver cancer therapeutics market in the US, the top five European countries (the UK, Germany, France, Italy and Spain) and Japan, with market forecasts until 2018. It provides in-depth analysis of the major marketed products, as well as insights into the liver cancer...
Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8

2 Liver Cancer Therapeutics Market to 2018 - Introduction 9

3 Liver Cancer Therapeutics Market to 2018 - Overview 10
3.1 Introduction 10
3.1.1 Benign Tumor 10
3.1.2 Primary Liver Cancer 10
3.1.3 Secondary Liver Cancer 10
3.2 Symptoms 11
3.3 Diagnosis 11
3.3.1 Laboratory Tests 11
3.3.2 Imaging Tests 11
3.3.3 Others 12
3.4 Treatment Options 12
3.4.1 Surgery 13
3.4.2 Non-surgical 13
3.4.3 General Treatment Algorithm 15
3.4.4 Treatment by Stage 16
3.4.5 New Technologies in Treatment 18

4 Liver Cancer Therapeutics Market to 2018 - Market Characterization and Forecasts 19
4.1 Revenue 19
4.2 Annual Cost of Therapy 22
4.3 Marketed Products 23
4.3.1 Nexavar 23
4.3.2 Miripla 25
4.4 Treatment Usage Pattern 27
4.4.1 Prevalence Population 28
4.4.2 Diagnosed Population 28
4.4.3 Prescription Population 28
4.5 Drivers and Barriers of Liver Cancer Therapeutics Market 28
4.5.1 Drivers 28
4.5.2 Barriers 29

5 Liver Cancer Therapeutics Market to 2018 - Geographical Landscape 30
5.1 US 30
5.1.1 Introduction 30
5.1.2 Revenue 30
5.1.3 Cost of Therapy 32
5.1.4 Treatment Usage Pattern 33
5.2 Top Five European Countries 34
5.2.1 Introduction 34
5.2.2 Revenue 34
5.2.3 Cost of Therapy 36
5.2.4 Treatment Usage Pattern 37
5.3 Japan 38
5.3.1 Introduction 38
5.3.2 Revenue 38
5.3.3 Cost of Therapy 39
5.3.4 Treatment Usage Pattern 40

6 Liver Cancer Therapeutics Market to 2018 - Pipeline Analysis 41
6.1 Introduction 41
6.2 R&D Product Pipeline by Stage of Development 43
6.2.1 Phase III 43
6.2.2 Phase II/III 44
6.2.3 Phase II 44
6.2.4 Phase I/II 45
6.2.5 Phase I 46
6.2.6 Pre-Clinical 47
6.2.7 Discovery 47
6.3 Profiles of Promising Molecules 48
6.3.1 PrevOnco 48
6.3.2 Ramucirumab 48
6.3.3 ThermoDox 49
6.3.4 Afinitor 50

7 Liver Cancer Therapeutics Market to 2018 - Competitive Landscape 51
7.1 Bayer 51
7.2 Dainippon Sumitomo Pharma 52

8 Liver Cancer Therapeutics Market to 2018 - Strategic Consolidations 53
8.1 Introduction 53
8.2 Deals by Geography 54
8.3 Deals by Year 55
8.4 Mergers and Acquisition Deals 56
8.4.1 Overview 56
8.4.2 Profiles of Major M&A Deals 57
8.5 Licensing Agreements 58
8.5.1 Overview 58
8.5.2 Profiles of Major Licensing Agreements 60
8.6 Co-Development Agreements 62
8.6.1 Overview 62
8.6.2 Profiles of Major Co-Development Agreements 63

9 Liver Cancer Therapeutics Market to 2018 - Appendix 64
9.1 Market Definitions 64
9.2 Abbreviations 64
9.3 Bibliography 66
9.4 Research Methodology 67
9.4.1 Coverage 67
9.4.2 Secondary Research 68
9.4.3 Primary Research 68
9.5 Therapeutic Landscape 69
9.5.2 Market Size by Geography 70
9.6 Geographical Landscape 71
9.7 Pipeline Analysis 71
9.8 Competitive Landscape 72
9.8.1 Expert Panel Validation 72
9.9 Contact Us 72
9.10 Disclaimer 72

List of Tables


Table 1: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue ($m), 2004-2011 19
Table 2: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts ($m), 2011-2018 19
Table 3: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue by Geography ($m), 2004-2011 20
Table 4: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts by Geography ($m), 2011-2018 21
Table 5: Liver Cancer Therapeutics Market, Top Seven Markets, Annual Cost of Therapy ($), 2004-2011 22
Table 6: Liver Cancer Therapeutics Market, Top Seven Markets, Annual Cost of Therapy ($), 2011-2018 22
Table 7: Liver Cancer Therapeutics Market to 2018, Nexavar, Clinical Trial Results 23
Table 8: Liver Cancer Therapeutics Market, Nexavar, Adverse Reactions Reported in Clinical Trial 24
Table 9: Liver Cancer Therapeutics Market, Nexavar, Approval History 25
Table 10: Liver Cancer Therapeutics Market, Top Seven Markets, Treatment Usage Pattern (‘000), 2004-2011 27
Table 11: Liver Cancer Therapeutics Market, Top Seven Markets, Treatment Usage Pattern (‘000), 2011-2018 27
Table 12: Liver Cancer Therapeutics Market, US, Revenue ($m), 2004-2011 30
Table 13: Liver Cancer Therapeutics Market, US, Revenue Forecasts ($m), 2011-2018 31
Table 14: Liver Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2004-2011 32
Table 15: Liver Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2011-2018 32
Table 16: Liver Cancer Therapeutics Market, US, Treatment Usage Pattern (‘000), 2004-2011 33
Table 17: Liver Cancer Therapeutics Market, US, Treatment Usage Pattern (‘000), 2011-2018 33
Table 18: Liver Cancer Therapeutics Market, Top Five European Countries, Revenue ($m), 2004-2011 35
Table 19: Liver Cancer Therapeutics Market, Top Five European Countries, Revenue Forecast ($m), 2011-2018 35
Table 20: Liver Cancer Therapeutics Market to 2018, Top Five European Countries, Annual Cost of Therapy ($), 2004-2011 36
Table 21: Liver Cancer Therapeutics Market to 2018, Top Five European Countries, Annual Cost of Therapy ($), 2011-2018 36
Table 22: Liver Cancer Therapeutics Market, Top Five European Countries, Treatment Usage Pattern (‘000), 2004-2011 37
Table 23: Liver Cancer Therapeutics Market, Top Five European Countries, Treatment Usage Pattern (‘000), 2011-2018 37
Table 24: Liver Cancer Therapeutics Market, Japan, Revenue ($m), 2004-2011 38
Table 25: Liver Cancer Therapeutics Market, Japan, Revenue Forecast ($m), 2011-2018 39
Table 26: Liver Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2004-2011 39
Table 27: Liver Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011-2018 39
Table 28: Liver Cancer Therapeutics Market, Japan, Treatment Usage Pattern (‘000), 2004-2011 40
Table 29: Liver Cancer Therapeutics Market, Japan, Treatment Usage Pattern (‘000), 2011-2018 40
Table 30: Liver Cancer Therapeutics Market, Global, Pipeline Products, by Stage of Development, 2012 42
Table 31: Liver Cancer Therapeutics Market, Global, Phase III Pipeline 43
Table 32: Liver Cancer Therapeutics Market, Global, Phase II/III Pipeline 44
Table 33: Liver Cancer Therapeutics Market, Global, Phase II Pipeline 44
Table 34: Liver Cancer Therapeutics Market, Global, Phase I/II Pipeline 45
Table 35: Liver Cancer Therapeutics Market, Global, Phase I Pipeline 46
Table 36: Liver Cancer Therapeutics Market, Global, Preclinical, 2012 47
Table 37: Liver Cancer Therapeutics Market, Global, Discovery, 2012 47
Table 38: Liver Cancer Therapeutics Market, Global, Bayer AG, Pharmaceutical Brands, 2012 51
Table 39: Liver Cancer Therapeutics Market, Global, Dainippon Sumitomo Pharma, Pharmaceutical Brands, 2012 52
Table 40: Liver Cancer Therapeutics Market, Global, Deals by Type of Agreement, 2007-2012 53
Table 41: Liver Cancer Therapeutics Market, Global, Deals by Geography, 2007-2012 54
Table 42: Liver Cancer Therapeutics Market, Global, Deals by Year, 2007-2012 55
Table 43: Liver Cancer Therapeutics Market, Global, Major M&A Deals, 2007-2012 56
Table 44: Liver Cancer Therapeutics Market, Global, Major Licensing Agreement Deals, 2007-2012 58
Table 45: Liver Cancer Therapeutics Market, Global, Major Co-Development Deals, 2007-2012 62

List of Figures


Figure 1: Liver Cancer Therapeutics Market, Global, Hepatocellular Carcinoma, Treatment Options, 2012 12
Figure 2: Liver Cancer Therapeutics Market, Global, Hepatocellular Carcinoma, General Treatment Algorithm 15
Figure 3: Liver Cancer Therapeutics Market, Global, Hepatocellular Carcinoma, Stage I and II, Treatment Algorithm 16
Figure 4: Liver Cancer Therapeutics Market, Global, Hepatocellular Carcinoma, Stage III and IV, Treatment Algorithm 17
Figure 5: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts ($m), 2004-2018 19
Figure 6: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts by Geography ($m), 2004-2018 20
Figure 7: Liver Cancer Therapeutics Market, Top Seven Markets, Annual Cost of Therapy ($), 2004-2018 22
Figure 8: Liver Cancer Therapeutics Market, Top Seven Markets, Treatment Usage Pattern (‘000), 2004-2018 27
Figure 9: Liver Cancer Therapeutics Market, Top Seven Markets, Drivers and Barriers, 2012 29
Figure 10: Liver Cancer Therapeutics Market, US, Revenue Forecasts ($m), 2004-2018 30
Figure 11: Liver Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2004-2018 32
Figure 12: Liver Cancer Therapeutics Market, US, Treatment Usage Pattern (‘000), 2004-2018 33
Figure 13: Liver Cancer Therapeutics Market, Top Five European Countries, Revenue Forecast ($m), 2004-2018 34
Figure 14: Liver Cancer Therapeutics Market, Top Five European Countries, Market Revenue ($m), 2004-2018 35
Figure 15: Liver Cancer Therapeutics Market, Top Five European Countries, Annual Cost of Therapy ($), 2004-2018 36
Figure 16: Liver Cancer Therapeutics Market, Top Five European Countries, Treatment Usage Pattern (‘000), 2004-2018 37
Figure 17: Liver Cancer Therapeutics Market, Japan, Revenue Forecast ($m), 2004-2018 38
Figure 18: Liver Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2004-2018 39
Figure 19: Liver Cancer Therapeutics Market, Japan, Treatment Usage Pattern (‘000), 2004-2018 40
Figure 20: Liver Cancer Therapeutics Market, Global, Pipeline Products, by Stage of Development, 2012 41
Figure 21: Liver Cancer Therapeutics Market, Global, Deals by Type of Agreement, 2007-2012 53
Figure 22: Liver Cancer Therapeutics Market, Global, Deals by Geography, 2007-2012 54
Figure 23: Liver Cancer Therapeutics Market, Global, Deals by Year, 2007-2012 55
Figure 24: GBI Research Market Forecasting Model 71

Upcoming Reports:

Poland: ready mixed concrete market
By - Williams and Marshal Strategy
rts and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the main market participants, the price fluctuations, the growth and demand drivers of the market and the factors, influencing its development. Last but not least, the report presents a general overview of the economy of Poland in 2008-2012 and a forecast for its development in the medium term. The report on the ready mixed concrete market in Poland includes: Analysis and dynamics of...
Cosmetic Procedures And Products Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Cosmetic procedures include elective surgical as well as nonsurgical procedures performed to reshape normal structures of the body. These procedures and cosmetic products are carried out to improve appearance of an individual thereby boosting self-confidence and self-esteem. The global market for cosmetic procedures and products is expanding both in terms of value and number of procedures performed annually. Several industry experts quote that ageing population, growing acceptance of cosmetic surgery, and interest of people for aesthetic reasons are the prime factors responsible for the...
Poland: wood boards market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the wood boards market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the wood boards market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Bristol-Myers Squibb Posts USD 3.9 billion Revenues in 2014 Second Quarter
Jul 30, 2014  
Leading bio-pharmaceutical company Bristol-Myers Squibb has registered revenues of USD 3.9 billion in the 2014 second quarter. This marks a 4% decrease from the same period in 2013. The global revenues of the company (excluding the divested Diabetes Alliance), saw a 7% increase. In this quarter, the company’s results were underlined by steady global sales of nearly each of its...
Novartiss Simbrinza gets approval from the EU
Jul 30, 2014  
Glaucoma patients in Europe can easily obtain Novartis’ Simbrinza eye drops which are a combination of brimonidine tartrate and brinzolamide and it is without a beta-blocker. This eye drop has got the approval of the European Commission. Unlike the inefficient treatment provided by monotherapy, this eye drop aims at treating intraocular pressure or IOP in adults with ocular hypertension...
Second Treaty Between Zealand And Boehringer Ingelheim
Jul 30, 2014  
Denmark based Pharma group Zealand Pharma and Germany’s Boehringer Ingelheim have signed an accord to formulate new medicines for advanced and effective treatment of cardio-metabolic maladies. The collaboration between these two Pharma groups involves a new therapeutic peptide project from the list of preclinical programs of Zealand Pharma.  Both these companies are aiming...
Fresh Lawsuits Hit General Motors
Jul 30, 2014  
This Tuesday, a lawsuit has hit General Motors on behalf of nearly 650 people regarding the faulty ignition switches in a number of cars, the reason why these cars were recalled from customers, which led to accidents that injured and even killed people.  The lawsuit was filed in the federal court of Manhattan, where dozens of cases against the company over the issue of faulty ignition...
Export market in New Zealand driven by innovative and high-value food products
Jul 29, 2014  
Demand for beverages and high value foods in Asia are driving the food and beverage industry in New Zealand. Also there is high demand for dairy products, seafood, meat and processed foods in the Asian economies which fuel the give an export boost to the economy of New Zealand.  Asia has a rapidly growing market for food which in turn is highly beneficial for New Zealand’s export...